Q-omics provides the consensus-scored RPSAP18 profile across patient tissues and cancer cell-line models. RPSAP18 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPSAP18 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, RPSAP18 RNA expression shows 16,047 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where RPSAP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP18 survival associations across molecular data types. RPSAP18 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP18 RNA expression–survival associations across cancer types. High RPSAP18 expression shows unfavorable associations in ACC, KICH, STAD, LIHC and LUAD, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPSAP18 RNA expression.
This table summarizes RPSAP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP18 shows lower tumor expression in KICH, LUSC, UCEC, LUAD and BLCA and higher tumor expression in LIHC. The LIHC box plot shows higher RPSAP18 RNA expression in tumor versus normal tissue (log2 FC = +0.536, t-test p < 0.001).
This table shows molecular features associated with RPSAP18 in patient tissues and cancer cell lines. In patient samples, RPSAP18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
